AstraZeneca announced that the European Commission (EC) approved Qtrilmet(metformin hydrochloride, saxagliptin, and dapagliflozin) modified-release tablets to improve glycaemic control in some adults with type-2 diabetes.
Across the trials, the combination of Forxiga, Onglyza, and metformin fared outperformed other combinations.
The EC has approved Qtrilmet to improve glycaemic control for ome patients.
Qtrilmet was approved in the US in May under the name Qternmet XR as an adjunct to diet and exercise to improve glycaemic control in adults with type-2 diabetes.
Qtrilmet is a once-daily oral medicine comprised of the selective sodium‑glucose co-transporter 2 (SGLT2) inhibitor Forxiga, the dipeptidyl peptidase‑4 (DPP‑4) inhibitor Onglyza and metformin hydrochloride extended-release.
AstraZeneca employs 1,500 in northern Delaware.
